Elicio Therapeutics Inc. (ELTX) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ELTX scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 6/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 5.75). Taken together, the weakest pillars are the cash engine and the smart-money signals, both of which sit at or near the bottom of their ranges. For a prospective investor, the implication is that the stock currently lacks internal cash generation, and the rating's inputs do not offer strong external validation to offset that. The forensic balance-sheet reading, while still weak, is the least negative of the five, which suggests the risk profile is driven more by operating burn than by leverage alone. Any upside case would need to rest on events outside the financial statements, such as clinical or regulatory developments, rather than on improving fundamentals visible in this data.

Elicio Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company is classified in this industry, though the source data does not describe its specific products, customers, or revenue model. Reported revenue for FY 2025 and FY 2024 is $0.0M in each period per the SEC financials, indicating no reported revenue in those years. Not available in source data for how the company monetizes its activities.

Per the SEC financials, the company reported operating losses in all three periods, with gross, operating, and net margins each at 0% per the market data. ROIC is -35% per the market data and FCF yield is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 5.75. Cash declined from $17.6M to $18.6M between periods only in the sense that FY 2025 is reported higher than FY 2024; debt fell from $20.0M to $9.4M across the same span. The balance sheet therefore shows reduced leverage alongside continued cash-consuming operations.

Per the recent news feed, the most prominent items are as follows:

• A Nature Medicine simultaneous publication tied to Phase 2 AMPLIFY-7P results presented at ESMO Congress 2026 (marked YELLOW, MARKET WIRE).
• An announcement that Phase 2 AMPLIFY-7P results will be presented at the SITC 2026 Annual Meeting (YELLOW, MARKET WIRE).
• Two short-term price reports showing gains to $1.89 and $1.83 (one marked GREEN, CATALYST).
• A stock price prediction piece (YELLOW, MARKET WIRE).

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The clinical presentations are the primary catalysts; the price-move items are market commentary. Risk watch items include the 52-week range of $1.44 to $16, indicating a large drawdown, and the price move of -5.4% in the latest session per the market data.

• What are the specific products, clinical programs, and partners of Elicio Therapeutics, and what is the status of the AMPLIFY-7P program?
• What is the company's cash runway given FY 2025 cash of $18.6M against FY 2025 FCF of $-37.0M?
• What are the terms, timing, and dilution implications of any financing needed to fund operations?
• What caused debt to decline from $20.0M to $9.4M, and what are the associated covenants or maturities?
• Why are P/E, EPS, and EV/EBITDA unavailable, and how would valuation be assessed for a company without reported revenue?